Clinical Trials
39 trialsTesting the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
MK-3475-01G
Merck Sharp & Dohme LLC
MK-3475-01I
Merck Sharp & Dohme LLC
MK-3475-01E
Merck Sharp & Dohme LLC
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Merus B.V.
NeoCOAST-2
AstraZeneca
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
KANNON
Avistone Biotechnology Co., Ltd.
REVIVE
University of Chicago
Evaluation of Canakinumab in High-Risk Former-Smokers
Ohio State University Comprehensive Cancer Center
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Boehringer Ingelheim
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Roswell Park Cancer Institute
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
LADOGA
AstraZeneca
SOUND
AstraZeneca
KontRASt-06
Novartis
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
N01-A-PICIT-GT
Peking University People's Hospital
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
National Cancer Institute (NCI)
VISUALIZE
Vergent Bioscience, Inc.
Testing the SurVaxM Vaccine for Lung Cancer Prevention
National Cancer Institute (NCI)
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
Memorial Sloan Kettering Cancer Center
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
A Study of SKB518 in Patients With Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
City of Hope Medical Center
Safety of Lung Cryobiopsy in People With Cancer
Memorial Sloan Kettering Cancer Center
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NIVIPI-Brain
Fundación GECP
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
AxeCan
HealthPartners Institute
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
M.D. Anderson Cancer Center
HARMONIC
Lantern Pharma Inc.